Table of Content

1. Key Insights

2. Executive Summary of Severe Toxicities in Lymphoma

3. SWOT Analysis

4. Severe Toxicities in Lymphoma Market Share (%) Distribution Overview at a Glance: By Country

5. Epidemiology and Market Methodology

6. Severe Toxicities in Lymphoma: Disease Background and Overview
6.1. Introduction
6.2. Staging of Lymphoma
6.3. Current therapeutic options for lymphoma
6.3.1. Chemotherapy
6.3.2. Targeted Therapies
6.3.3. Radiation Therapy
6.4. Severe Toxicities due to Lymphoma treatment
6.4.1. Cardiovascular Diseases
6.4.2. Pulmonary Diseases
6.4.3. Hormone problems
6.4.4. Second cancer
6.4.5. CAR T-cell toxicities
6.4.6. Other late effects
6.5. Risk factors for toxicities in lymphoma
6.6. Diagnosis
6.6.1. Tests for Lung disorders due to toxicities
6.6.2. Tests for thyroid abnormalities due to toxicities
6.6.3. Tests for fertility in females
6.6.4. Tests for Cardiovascular disorders due to toxicities
6.6.5. Tests for Second Cancers due to toxicities

7. Epidemiology and Patient Population
7.1. Epidemiology Key Findings
7.2. Assumptions and Rationale: 7MM
7.3. 7MM Epidemiology
7.3.1. Total Incident Cases of lymphoma in the 7MM
7.3.2. Type-specific Incident cases of Lymphoma in 7MM
7.3.3. Stage-Specific Incidence of Lymphoma in the 7MM
7.3.4. Chemotherapy Treated Lymphoma Patients in the 7MM
7.3.5. Frequency of Severe Toxicities in Lymphoma Patients in the 7MM
7.4. The United States Epidemiology
7.4.1. `Total Incident cases of Lymphoma in the United States
7.4.2. Type-specific Incident cases of Lymphoma in the United States
7.4.3. Stage-Specific Incidence of Lymphoma in the United States
7.4.4. Chemotherapy Treated Lymphoma Patients in the United States
7.4.5. Frequency of Severe Toxicities in Lymphoma Patients in the United States
7.5. EU-5 Epidemiology
7.6. Germany
7.6.1. Total Incident cases of Lymphoma in Germany
7.6.2. Type-specific Incident cases of Lymphoma in Germany
7.6.3. Stage-Specific Incidence of Lymphoma in Germany
7.6.4. Chemotherapy Treated Lymphoma Patients in Germany
7.6.5. Frequency of Severe Toxicities in Lymphoma Patients in Germany
7.7. France
7.7.1. Total Incident cases of Lymphoma in France
7.7.2. Type-specific Incident cases of Lymphoma in France
7.7.3. Stage-Specific Incidence of Lymphoma in France
7.7.4. Chemotherapy Treated Lymphoma Patients in France
7.7.5. Frequency of Severe Toxicities in Lymphoma Patients in France
7.8. Italy
7.8.1. Total Incident cases of Lymphoma in Italy
7.8.2. Type-specific Incident cases of Lymphoma in Italy
7.8.3. Stage-Specific Incidence of Lymphoma in Italy
7.8.4. Chemotherapy Treated Lymphoma Patients in Italy
7.8.5. Frequency of Severe Toxicities in Lymphoma Patients in Italy
7.9. Spain
7.9.1. Total Incident cases of Lymphoma in Spain
7.9.2. Type-specific Incident cases of Lymphoma in Spain
7.9.3. Stage-Specific Incidence of Lymphoma in Spain
7.9.4. Chemotherapy Treated Lymphoma Patients in Spain
7.9.5. Frequency of Severe Toxicities in Lymphoma Patients in Spain
7.10. The United Kingdom
7.10.1. Total Incident cases of Lymphoma in the United Kingdom
7.10.2. Type-specific Incident cases of Lymphoma in the United Kingdom
7.10.3. Stage-Specific Incidence of Lymphoma in the United Kingdom
7.10.4. Chemotherapy Treated Lymphoma Patients in the United Kingdom
7.10.5. Frequency of Severe Toxicities in Lymphoma Patients in the United Kingdom
7.11. Japan Epidemiology
7.11.1. Total Incident cases of Lymphoma in Japan
7.11.2. Type-specific Incident cases of Lymphoma in Japan
7.11.3. Stage-Specific Incidence of Lymphoma in Japan
7.11.4. Chemotherapy Treated Lymphoma Patients in Japan
7.11.5. Frequency of Severe Toxicities in Lymphoma Patients in Japan

8. Current Treatment Practices: Severe Toxicities in Lymphoma
8.1. Cardiovascular Disease
8.2. Lung Disease
8.3. Thyroid Abnormalities
8.4. Female Fertility

9. Unmet Needs

10. Patient Journey?

11. Key Endpoints in Severe Toxicities in Lymphoma Clinical Trials

12. Emerging Therapies
12.1. AB-205: Angiocrine Bioscience
12.1.1. Product Description
12.1.2. Other Developmental Activities
12.1.3. Clinical Development
12.1.4. Safety and Efficacy

13. Severe Toxicities in Lymphoma Seven Major Market Analysis
13.1. Key Finding
13.2. 7MM Market Size
13.2.1. Total Market Size of Severe Toxicities in Lymphoma in the 7MM
13.2.2. Total Market size of Severe Toxicities in Lymphoma by Therapies in the 7MM
13.3. The United States Market Size
13.3.1. Total Market size of Severe Toxicities in Lymphoma in the United States
13.4. EU-5 Market Size
13.5. Germany Market Size
13.5.1. Total Market size of Severe Toxicities in Lymphoma in Germany
13.6. France Market Size
13.6.1. Total Market size of Severe Toxicities in Lymphoma in France
13.7. Italy Market Size
13.7.1. Total Market size of Severe Toxicities in Lymphoma in Italy
13.8. Spain Market Size
13.8.1. Total Market size of Severe Toxicities in Lymphoma in Spain
13.9. The United Kingdom Market Size
13.9.1. Total Market size of Severe Toxicities in Lymphoma in the United Kingdom
13.10. Japan Market Size
13.10.1. Total Market size of Severe Toxicities in Lymphoma in Japan

14. Market Access and Reimbursement

15. Market Drivers

16. Market Barriers

17. Appendix
17.1. Bibliography
17.2. Report Methodology

18. DelveInsight Capabilities

19. Disclaimer

20. About DelveInsight



List of Figures


Figure 1: Severe Toxicities in Lymphoma SWOT Analysis
Figure 2: Abnormal cells in Lymphoma
Figure 3: Potential toxicities due to lymphoma treatment
Figure 4: Common cancers after lymphoma treatment
Figure 5: CRS toxicities by organ system
Figure 6: Spirometry Test
Figure 7: Echocardiography
Figure 8: Global Heat Map of Lymphoma
Figure 9: Total Incident Cases of lymphoma in the 7MM (2018–2030)
Figure 10: Type-specific Incident cases of Lymphoma in 7MM (2018–2030)
Figure 11: Stage-Specific Incidence of Lymphoma in the 7MM (2018–2030)
Figure 12: Chemotherapy Treated Lymphoma Patients in the 7MM (2018–2030)
Figure 13: Frequency of Severe Toxicities in Lymphoma Patients in the 7MM (2018–2030)
Figure 14: Total Incident cases of Lymphoma in the United States (2018–2030)
Figure 15: Type-specific Incident cases of Lymphoma in the United States (2018–2030)
Figure 16: Stage-Specific Incidence of Lymphoma in the United States (2018–2030)
Figure 17: Chemotherapy Treated Lymphoma Patients in the United States (2018–2030)
Figure 18: Frequency of Severe Toxicities in Lymphoma Patients in the United States (2018–2030)
Figure 19: Total Incident cases of Lymphoma in Germany (2018–2030)
Figure 20: Type-specific Incident cases of Lymphoma in Germany (2018–2030)
Figure 21: Stage-Specific Incidence of Lymphoma in Germany (2018–2030)
Figure 22: Chemotherapy Treated Lymphoma Patients in Germany (2018–2030)
Figure 23: Frequency of Severe Toxicities in Lymphoma Patients in Germany (2018–2030)
Figure 24: Total Incident cases of Lymphoma in France (2018–2030)
Figure 25: Type-specific Incident cases of Lymphoma in France (2018–2030)
Figure 26: Stage-Specific Incidence of Lymphoma in France (2018–2030)
Figure 27: Chemotherapy Treated Lymphoma Patients in France (2018–2030)
Figure 28: Frequency of Severe Toxicities in Lymphoma Patients in France (2018–2030)
Figure 29: Total Incident cases of Lymphoma in Italy (2018–2030)
Figure 30: Type-specific Incident cases of Lymphoma in Italy (2018–2030)
Figure 31: Stage-Specific Incidence of Lymphoma in Italy (2018–2030)
Figure 32: Chemotherapy Treated Lymphoma Patients in Italy (2018–2030)
Figure 33: Frequency of Severe Toxicities in Lymphoma Patients in Italy (2018–2030)
Figure 34: Total Incident cases of Lymphoma in Spain (2018–2030)
Figure 35: Type-specific Incident cases of Lymphoma in Spain (2018–2030)
Figure 36: Stage-Specific Incidence of Lymphoma in Spain (2018–2030)
Figure 37: Chemotherapy Treated Lymphoma Patients in Spain (2018–2030)
Figure 38: Frequency of Severe Toxicities in Lymphoma Patients in Spain (2018–2030)
Figure 39: Total Incident cases of Lymphoma in the United Kingdom (2018–2030)
Figure 40: Type-specific Incident cases of Lymphoma in the United kingdom (2018–2030)
Figure 41: Stage-Specific Incidence of Lymphoma in the United Kingdom (2018–2030)
Figure 42: Chemotherapy Treated Lymphoma Patients in the United Kingdom (2018–2030)
Figure 43: Frequency of Severe Toxicities in Lymphoma Patients in the United Kingdom (2018–2030)
Figure 44: Total Incident cases of Lymphoma in Japan (2018–2030)
Figure 45: Type-specific Incident cases of Lymphoma in Japan (2018–2030)
Figure 46: Stage-Specific Incidence of Lymphoma in Japan (2018–2030)
Figure 47: Chemotherapy Treated Lymphoma Patients in Japan (2018–2030)
Figure 48: Frequency of Severe Toxicities in Lymphoma Patients in Japan (2018–2030)


List of Tables


Table 1: Summary of Severe Toxicities in Lymphoma Market, Epidemiology, and Key Events (2018–2030)
Table 2: Type of B-cell Lymphoma
Table 3: Type of T cell Lymphoma
Table 4: Chemotherapy drugs for Non-Hodgkin Lymphoma
Table 5: Chemotherapy Drugs for Hodgkin Lymphoma
Table 6: Total Incident Cases of lymphoma in the 7MM (2018–2030)
Table 7: Type-specific Incident cases of Lymphoma in 7MM (2018–2030)
Table 8: Stage-Specific Incidence of Lymphoma in the 7MM (2018–2030)
Table 9: Chemotherapy Treated Lymphoma Patients in the 7MM (2018–2030)
Table 10: Frequency of Severe Toxicities in Lymphoma Patients in the 7MM (2018–2030)
Table 11: Total Incident cases of Lymphoma in the United States (2018–2030)
Table 12: Type-specific Incident cases of Lymphoma in the United States (2018–2030)
Table 13: Stage-Specific Incidence of Lymphoma in the United States (2018–2030)
Table 14: Chemotherapy Treated Lymphoma Patients in the United States (2018–2030)
Table 15: Frequency of Severe Toxicities in Lymphoma Patients in the United States (2018–2030)
Table 16: Total Incident cases of Lymphoma in Germany (2018–2030)
Table 17: Type-specific Incident cases of Lymphoma in Germany (2018–2030)
Table 18: Stage-Specific Incidence of Lymphoma in Germany (2018–2030)
Table 19: Chemotherapy Treated Lymphoma Patients in Germany (2018–2030)
Table 20: Frequency of Severe Toxicities in Lymphoma Patients in Germany (2018–2030)
Table 21: Total Incident cases of Lymphoma in France (2018–2030)
Table 22: Type-specific Incident cases of Lymphoma in France (2018–2030)
Table 23: Stage-Specific Incidence of Lymphoma in France (2018–2030)
Table 24: Chemotherapy Treated Lymphoma Patients in France (2018–2030)
Table 25: Frequency of Severe Toxicities in Lymphoma Patients in France (2018–2030)
Table 26: Total Incident cases of Lymphoma in Italy (2018–2030)
Table 27: Type-specific Incident cases of Lymphoma in Italy (2018–2030)
Table 28: Stage-Specific Incidence of Lymphoma in Italy (2018–2030)
Table 29: Chemotherapy Treated Lymphoma Patients in Italy (2018–2030)
Table 30: Frequency of Severe Toxicities in Lymphoma Patients in Italy (2018–2030)
Table 31: Total Incident cases of Lymphoma in Spain (2018–2030)
Table 32: Type-specific Incident cases of Lymphoma in Spain (2018–2030)
Table 33: Stage-Specific Incidence of Lymphoma in Spain (2018–2030)
Table 34: Chemotherapy Treated Lymphoma Patients in Spain (2018–2030)
Table 35: Frequency of Severe Toxicities in Lymphoma Patients in Spain (2018–2030)
Table 36: Total Incident cases of Lymphoma in the United Kingdom (2018–2030)
Table 37: Type-specific Incident cases of Lymphoma in the United kingdom (2018–2030)
Table 38: Stage-Specific Incidence of Lymphoma in the United Kingdom (2018–2030)
Table 39: Chemotherapy Treated Lymphoma Patients in the United Kingdom (2018–2030)
Table 40: Frequency of Severe Toxicities in Lymphoma Patients in the United Kingdom (2018–2030)
Table 41: Total Incident cases of Lymphoma in Japan (2018–2030)
Table 42: Type-specific Incident cases of Lymphoma in Japan (2018–2030)
Table 43: Stage-Specific Incidence of Lymphoma in Japan (2018–2030)
Table 44: Chemotherapy Treated Lymphoma Patients in Japan (2018–2030)
Table 45: Frequency of Severe Toxicities in Lymphoma Patients in Japan (2018–2030)
Table 46: AB-205, Clinical Trial Description
Table 47: 7MM Market Size of Severe Toxicities In Lymphoma, in USD Million (2018–2030)
Table 48: 7MM Market Size of Severe Toxicities In Lymphoma by Therapies, in USD Million (2018–2030)
Table 49: Total United States Market Size of Severe Toxicities In Lymphoma, in USD Million (2018–2030)
Table 50: The United States Market Size of Severe Toxicities In Lymphoma by Therapies, in USD Million (2018–2030)
Table 51: Germany Market Size of Severe Toxicities In Lymphoma, in USD Million (2018–2030)
Table 52: Germany Market Size of Severe Toxicities In Lymphoma by Therapies, in USD Million (2018–2030)
Table 53: France Market Size of Severe Toxicities In Lymphoma, in USD Million (2018–2030)
Table 54: France Market Size of Severe Toxicities In Lymphoma by Therapies, in USD Million (2018–2030)
Table 55: Italy Market Size of Severe Toxicities In Lymphoma, in USD Million (2018–2030)
Table 56: Italy Market Size of Severe Toxicities In Lymphoma by Therapies, in USD Million (2018–2030)
Table 57: Spain Market Size of severe toxicities in lymphoma, in USD Million (2018–2030)
Table 58: Spain Market Size of Severe Toxicities In Lymphoma by Therapies, in USD Million (2018–2030)
Table 59: The United Kingdom Market Size of Severe Toxicities In Lymphoma, in USD Million (2018–2030)
Table 60: The United Kingdom Market Size of Severe Toxicities In Lymphoma by Therapies, in USD Million (2018–2030)
Table 61: Japan Market Size of severe toxicities in lymphoma, in USD Million (2018–2030)
Table 62: Japan Market Size of Severe Toxicities In Lymphoma by Therapies, in USD Million (2018–2030)